1 Medical Doctor, Primary Care Bembibre Center, León, Spain; University of Leon – UNILEON (Spain).
2 Medical Doctor, University of Salamanca, Salamanca, Spain.
3 Nursing, Bierzo Hospital, Ponferrada (León), Spain.
4 Profesor, University of León, IBIOMED, León, Spain.
Research Article
World Journal of Biology Pharmacy and Health Sciences, 2021, 06(01), 026-038.
Article DOI: 10.30574/wjbphs.2021.6.1.0013
Received on 04 February 2021; revised on 11 April 2021; accepted on 14 April 20211
Objective: Describe the treatment of the patient with atherogenic dyslipidaemia (AD) in routine Primary Care clinical practice.
Methodology: Observational, descriptive, cross-sectional study based on a structured questionnaire. The content of the questionnaire was based on a review of the literature and was validated by 3 AD experts. It included 23 questions and was addressed to primary care physicians. This sub study will analyze questions related to the treatment of AD.
Results: A total of 1,029 Primary Care physicians (67.06% men) participated in the study. Most work in urban areas (55.9%) and attended to a mean of 79.9 (SD: 89.85) patients with AD per month. Most (95.63%) considered that the first step in treatment is lifestyle modification. For the AD approach associated with obesity in primary prevention, 74% of the participants advised lifestyle modifications and in turn evaluated the need for pharmacological treatment. In patients with moderate elevations of LDL-C and DA treated with statins, 90% of doctors associated fibrates. In these patients, 93% agreed or fully agreed that fenofibrate is the most appropriate fibrate for their combination with statins. 19% consider the genfibrocil association. In patients in secondary prevention and AD, treated with statins with LDL-C in therapeutic objectives, the majority of participants (94.46%) added a fibrate and 70% combined statins and fibrates from the start of treatment.
Conclusions: Although the level of inculcation of knowledge about the therapeutic management of AD is highly acceptable in some cases, there are parts that need to be modified, especially the poor association of statins with genfibrocil.
Atherogenic dyslipidaemia; Primary care physicians; Treatment
Get Your e Certificate of Publication using below link
Preview Article PDF
Capón Álvarez J, Díaz Fernández B, Díaz Rodríguez A, Crespo García N, Cuello Estrada C, García Ferreiro T, Rodríguez Pérez, EM, Méndez Rodríguez E, Fernández Álvarez, A, Seco Calvo JA. Treatment of atherogenic dyslipidaemia in Primary Care in Spain.World Journal of Biology Pharmacy and Health Sciences, 2021, 06(01), 026-038. Article DOI: https://doi.org/10.30574/wjbphs.2021.6.1.0013